CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Otsuka Pakistan Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Otsuka Pakistan Ltd
30-B
S.M.C.H. Society, Off: Shahrah-e-Faisal
Phone: +92 2134528651p:+92 2134528651 KARACHI, 74400  Pakistan Ticker: OTSUOTSU
This is a Subsidiary, click here for the Parent Company
Business Summary
Otsuka Pakistan Limited is a Pakistan-based company engaged in the manufacturing, marketing and distribution of intravenous (IV) infusions and trading in pharmaceutical products, nutritional foods, and medical equipment. It is primarily focused on IV solutions and has a range of electrolyte solutions, carbohydrate solutions, and clinical nutrition products. Its products include intravenous solutions, medical devices, clinical nutrition, therapeutic drugs and nutraceutical products. Its intravenous solutions include electrolyte solutions, standard solutions, ampoules, OTSUZOL, OTSUMOL infusion, and others. Its medical devices include urea breath test (UBT), Plasline solution, EUCATECH and Support C. Its clinical nutrition products include Aminoleban Oral, AMINOVEL 600, PAN-AMIN G, and AMINOLEBAN INJECTION. Its therapeutic drugs include Pletaal and Mucosta. Its nutraceutical products include ORTie, which is a special combination of dry salts and vitamin C to be mixed with safe water.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20236/30/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board MikioBando 11/1/2016 11/1/2016
Chief Executive Officer, Director HanifSattar 1/1/2017 1/1/2017
Chief Financial Officer Sajid AliKhan 8/28/2018 2/27/2012
7 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 12,100,000 (As of 12/31/2023)
Stock Exchange: PSX
Fax Number: +92 2134549857


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024